| abstract |
The present invention relates to compounds of formula I, in which A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the receptor for endothelial differentiation gene 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also called LPA1 receptor, and they are useful for the treatment of diseases such as atherosclerosis, infarction of myocardium and heart failure, for example. The invention further relates to processes for preparing the compounds of formula I, to their use and to pharmaceutical compositions comprising them. |